These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25573956)

  • 1. Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.
    Zhang Y; Wang Q; Chen L; Yang HS
    Mol Cancer Ther; 2015 Mar; 14(3):799-809. PubMed ID: 25573956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
    Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
    Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
    Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
    Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.
    Leiphrakpam PD; Agarwal E; Mathiesen M; Haferbier KL; Brattain MG; Chowdhury S
    Oncol Rep; 2014 Jan; 31(1):87-94. PubMed ID: 24173770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
    Flanigan SA; Pitts TM; Eckhardt SG; Tentler JJ; Tan AC; Thorburn A; Leong S
    Clin Cancer Res; 2010 Nov; 16(22):5436-46. PubMed ID: 20943761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
    McKinley ET; Bugaj JE; Zhao P; Guleryuz S; Mantis C; Gokhale PC; Wild R; Manning HC
    Clin Cancer Res; 2011 May; 17(10):3332-40. PubMed ID: 21257723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
    Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
    Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
    Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
    BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.
    Zinn RL; Gardner EE; Marchionni L; Murphy SC; Dobromilskaya I; Hann CL; Rudin CM
    Mol Cancer Ther; 2013 Jun; 12(6):1131-9. PubMed ID: 23515613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
    Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
    Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
    Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
    Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.
    Tandon R; Senthil V; Nithya D; Pamidiboina V; Kumar A; Malik S; Chaira T; Diwan M; Gupta P; Venkataramanan R; Malik R; Das B; Dastidar SG; Cliffe I; Ray A; Bhatnagar PK
    Eur J Pharmacol; 2013 Jul; 711(1-3):19-26. PubMed ID: 23639757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma.
    Wang Q; Zhu J; Wang YW; Dai Y; Wang YL; Wang C; Liu J; Baker A; Colburn NH; Yang HS
    Oncogene; 2017 Nov; 36(45):6225-6234. PubMed ID: 28692058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression.
    Saxena A; Shoeb M; Ramana KV; Srivastava SK
    Eur J Cancer; 2013 Oct; 49(15):3311-9. PubMed ID: 23827854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.